<?xml version='1.0' encoding='utf-8'?>
<document id="30044681"><sentence text="In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin."><entity charOffset="57-67" id="DDI-PubMed.30044681.s1.e0" text="mavacamten" /></sentence><sentence text="Mavacamten is a small molecule modulator of cardiac myosin designed as an orally administered drug for the treatment of patients with hypertrophic cardiomyopathy"><entity charOffset="0-10" id="DDI-PubMed.30044681.s2.e0" text="Mavacamten" /></sentence><sentence text=" The current study objectives were to assess the preclinical pharmacokinetics of mavacamten for the prediction of human dosing and to establish the potential need for clinical pharmacokinetic studies characterizing drug-drug interaction potential"><entity charOffset="81-91" id="DDI-PubMed.30044681.s3.e0" text="mavacamten" /></sentence><sentence text=" Mavacamten does not inhibit CYP enzymes, but at high concentrations relative to anticipated therapeutic concentrations induces CYP2B6 and CYP3A4 enzymes in vitro" /><sentence text=" Mavacamten showed high permeability and low efflux transport across Caco-2 cell membranes"><entity charOffset="1-11" id="DDI-PubMed.30044681.s5.e0" text="Mavacamten" /></sentence><sentence text=" In human hepatocytes, mavacamten was not a substrate for drug transporters OATP, OCT and NTCP" /><sentence text=" Mavacamten was determined to have minimal drug-drug interaction risk" /><sentence text=" In vitro mavacamten metabolite profiles included phase I- and phase II-mediated metabolism cross-species" /><sentence text=" Major pathways included aromatic hydroxylation (M1), aliphatic hydroxylation (M2); N-dealkylation (M6), and glucuronidation of the M1-metabolite (M4)" /><sentence text=" Reaction phenotyping revealed CYPs 2C19 and 3A4/3A5 predominating" /><sentence text=" Mavacamten demonstrated low clearance, high volume of distribution, long terminal elimination half-life and excellent oral bioavailability cross-species" /><sentence text=" Simple four-species allometric scaling led to predicted plasma clearance, volume of distribution and half-life of 0" /><sentence text="51 mL/min/kg, 9" /><sentence text="5 L/kg and 9 days, respectively, in human" /><sentence text="" /></document>